Rice Hall James & Associates LLC Has $6.99 Million Holdings in Taysha Gene Therapies, Inc. $TSHA

Rice Hall James & Associates LLC increased its holdings in shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) by 119.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,270,645 shares of the company’s stock after buying an additional 692,527 shares during the quarter. Rice Hall James & Associates LLC’s holdings in Taysha Gene Therapies were worth $6,989,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in the business. Squarepoint Ops LLC raised its stake in Taysha Gene Therapies by 137.7% during the 4th quarter. Squarepoint Ops LLC now owns 471,577 shares of the company’s stock worth $2,594,000 after buying an additional 273,225 shares during the period. Panagora Asset Management Inc. bought a new position in Taysha Gene Therapies during the 4th quarter worth about $64,000. Focus Partners Wealth bought a new position in Taysha Gene Therapies during the 4th quarter worth about $1,625,000. Healthcare of Ontario Pension Plan Trust Fund bought a new position in Taysha Gene Therapies during the 4th quarter worth about $20,471,000. Finally, Barclays PLC increased its holdings in Taysha Gene Therapies by 7.6% during the 4th quarter. Barclays PLC now owns 5,539,001 shares of the company’s stock worth $30,465,000 after purchasing an additional 390,889 shares in the last quarter. Institutional investors and hedge funds own 77.70% of the company’s stock.

Insider Buying and Selling at Taysha Gene Therapies

In other news, insider Sukumar Nagendran sold 200,000 shares of the firm’s stock in a transaction dated Friday, April 10th. The stock was sold at an average price of $4.46, for a total value of $892,000.00. Following the completion of the transaction, the insider owned 1,136,410 shares in the company, valued at $5,068,388.60. This trade represents a 14.97% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 3.78% of the stock is owned by insiders.

Taysha Gene Therapies Price Performance

Shares of NASDAQ TSHA opened at $5.97 on Tuesday. The stock has a market capitalization of $1.72 billion, a price-to-earnings ratio of -15.71 and a beta of 1.19. The business has a 50-day moving average of $5.80 and a 200-day moving average of $5.19. The company has a debt-to-equity ratio of 0.23, a current ratio of 14.04 and a quick ratio of 14.04. Taysha Gene Therapies, Inc. has a fifty-two week low of $2.25 and a fifty-two week high of $7.30.

Taysha Gene Therapies (NASDAQ:TSHA) last announced its quarterly earnings data on Wednesday, May 6th. The company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.02). As a group, sell-side analysts predict that Taysha Gene Therapies, Inc. will post -0.5 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Taysha Gene Therapies in a report on Friday, March 27th. Canaccord Genuity Group increased their target price on Taysha Gene Therapies from $14.00 to $17.00 and gave the stock a “buy” rating in a report on Monday, April 6th. Chardan Capital reiterated a “buy” rating and set a $12.00 target price on shares of Taysha Gene Therapies in a report on Thursday, March 19th. Wall Street Zen cut Taysha Gene Therapies from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Finally, Truist Financial upgraded Taysha Gene Therapies to a “strong-buy” rating in a report on Wednesday, March 25th. Two research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $11.64.

Taysha Gene Therapies Profile

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.